Provenge News and Research

RSS
New clinical trial tests immunotherapy drug for prostate cancer patients on active surveillance

New clinical trial tests immunotherapy drug for prostate cancer patients on active surveillance

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Dendreon shareholders call for annual elections to increase board independence and accountability

Dendreon shareholders call for annual elections to increase board independence and accountability

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Dendreon plans to make PROVENGE available in Europe

Dendreon plans to make PROVENGE available in Europe

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Edison Investment Research's report examines long-term investment case for Bavarian Nordic

Edison Investment Research's report examines long-term investment case for Bavarian Nordic

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Cancer immunotherapies promise to be a new tool in fight against cancer

Cancer immunotherapies promise to be a new tool in fight against cancer

New immunotherapies are seldom developed for childhood cancer

New immunotherapies are seldom developed for childhood cancer

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Certain patients with prostate cancer may benefit from Provenge clinical trial

Certain patients with prostate cancer may benefit from Provenge clinical trial

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

Dendreon 2011 product revenue increases to $213.5M

Dendreon 2011 product revenue increases to $213.5M

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

FDA prioritizes review of Ra-223 and MDV3100 for treating CRPC

Scientists develop new vaccine to treat cancer at pre-clinical level

Scientists develop new vaccine to treat cancer at pre-clinical level